GCG and diabetes mellitus: An additional subgroup analysis revealed that the effect size of a reduction in MAGE levels in patients with diabetes treated with GLP-1 agonists as add-on therapy was −0.60 (SMD; 95% CI = −0.88, −0.33; p < 0.00001).